
SeQuent Scientific announces Q1 - FY 2014-15 Results

Consolidated Revenues at Rs.1127 mio

Records 27% increase in operating profits during the quarter

EBIDTA increase to Rs. 74 mio against Rs. 58 mio in Q1, 2013

Key strategic initiatives completed

Bangalore, August 13, 2014, SeQuent Scientific Limited today announced its unaudited consolidated financial results for the quarter ended June 30, 2014.

Financial Highlights

- Sharper focus on execution leads to 27% increase in operating profits, inspite of lower revenue
- EBITDA at Rs. 74 mio as against Rs. 58 mio in the Q1 FY 2013-14.
- Marginal dip in sales for the quarter on account of lower production due to shutdown at Mangalore facility to facilitate expansion.

Operational highlights

- Veterinary division branded as Alivira
- Alivira's state of art Vizag plant commenced trial production
- Significant expansion completed at US FDA approved Mangalore facility
- Completed sale of Specialty chemical business to Songwon Industrial Group Corporation, South Korea for a total cash consideration of Rs. 120 Crores.
- First product commercialised in US market under profit share arrangement

Commenting on the occasion, Mr. Manish Gupa – CEO stated that “We are pleased with the improved operational performance during the quarter which is reflected in the EBITDA growth inspite of lower revenue, on account of shutdown at Mangalore facility for expansion. With the recent completion of our key strategic initiatives including capacity expansions, we are confident of accelerating our performance in the coming quarters”.

About Sequent Scientific Limited.

SeQuent Scientific Limited, listed on the Bombay Stock Exchange Limited (stock code: 512529) is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services and CRAMS. SeQuent is the world's largest producer of Anthelmintics.

Please visit www.sequent.in for additional information.

For additional information, please contact

SeQuent Scientific Limited

Manish Gupta, CEO

manish@sequent.in

Tel: +91 22 41114714

Kannan P R, CFO

Kannan.pr@sequent.in

Tel: +91 80 67840327

Mr. Rohit Yagnik, Fortuna PR

+91 98338 07272; rohit@fortunapr.in